Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
4 drugs in development
By Therapeutic Area
top 2
R&D Momentum
65/100
Pipeline Velocity
25/100
Trial Completion Rate
55/100
Pipeline Concentration
63/100
Pipeline Freshness
54/100
Strategic Signals
Activity
Last 14 days
A Phase 2 Study of Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer
GU-254: A Phase II Trial of Risk-Enabled Therapy After Initiating Neoadjuvant Enfortumab Vedotin/Pembrolizumab for Bladder Cancer (RETAIN-3)
A Phase II Investigation of Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer Patients Managed With Primary (Chemo) Radiation
Adaptive Radiation for Abdominopelvic Metastases (ARAM)
Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy
Dose Escalated CT-Based Adaptive Stereotactic Body Radiation Therapy Among Patients With Intermediate- and Favorable High- Risk Prostate Cancer (DE-CART)
Redefining The Use Of A FOLFIRINOX-Like Regimen In the Front Line In Older Patients With Metastatic Pancreatic Cancer
Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer: Phase I Dose Escalation Study
Exploring the Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy: A Prospective Study
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)